Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mov Disord ; 39(2): 350-359, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37886872

ABSTRACT

BACKGROUND: There remains uncertainty as to the optimal way to initiate therapy for Parkinson's disease (PD) to maximize benefit and minimize adversity. OBJECTIVES: The objective was to determine if P2B001 (a fixed, low-dose, extended-release [ER] combination of pramipexole 0.6 mg and rasagiline 0.75 mg) is superior to each of its components and compare its safety and efficacy to optimized treatment with marketed doses of pramipexole-ER. METHODS: This was a 12-week, double-blind study (NCT03329508). Total of 544 untreated patients with PD were randomized (2:2:2:1) to treatment with P2B001, its individual components (pramipexole-ER 0.6 mg or rasagiline-ER 0.75 mg), or commercial doses of pramipexole-ER titrated to optimal dose (1.5-4.5 mg). The primary endpoint was change from baseline to week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III. The key secondary endpoint was the change from baseline in the Epworth Sleepiness Scale (ESS) for P2B001 versus the titrated dose of pramipexole-ER. RESULTS: P2B001 provided superior efficacy compared to each of its components; mean (95% CI) treatment differences in UPDRS II + III scores were -2.66 (95% CI, -4.33 to -1.00) versus pramipexole-ER 0.6 mg (P = 0.0018) and - 3.30 (95% CI, -4.96 to -1.63) versus rasagiline-ER 0.75 mg (P < 0.0001). P2B001 had comparable efficacy with the titrated dose of pramipexole-ER (mean, 3.2 mg), but significantly less worsening in daytime-sleepiness (ESS treatment difference: -2.66 [95% CI, -3.50 to -1.81]; P < 0.0001). P2B001 was well-tolerated with fewer sleep-related and dopaminergic adverse events than titrated doses of pramipexole-ER including somnolence, orthostatic hypotension, and neuropsychiatric side effects. CONCLUSIONS: P2B001 had superior efficacy to its individual components and was comparable with commercially used doses of pramipexole-ER with less worsening of sleepiness and fewer dopaminergic adverse events. These findings support considering once-daily P2B001 as initial therapy for patients with early PD. © 2023 International Parkinson and Movement Disorder Society.


Subject(s)
Indans , Parkinson Disease , Humans , Pramipexole , Parkinson Disease/drug therapy , Antiparkinson Agents/adverse effects , Sleepiness , Benzothiazoles/therapeutic use , Double-Blind Method
2.
J Parkinsons Dis ; 5(4): 837-45, 2015.
Article in English | MEDLINE | ID: mdl-26444090

ABSTRACT

BACKGROUND: Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD concentrations and maintain them to allow a dosing interval of ∼6 hours. OBJECTIVE: To extensively analyze the dosing data collected in IPX066 studies during open-label conversions from IR CD-LD alone or with entacapone (CLE) and identify patterns relevant for managing conversion in the clinical setting. METHODS: Patients had ≥2.5 hours/day of "off" time despite a stable IR or CLE regimen. Suggested initial dosing conversion tables based on prior LD daily dosage were provided. RESULTS: Of 450 patients previously treated with IR CD-LD and 110 with CLE, 87.3% and 82.7% completed conversion to IPX066, respectively. At the end of conversion, average IPX066 LD daily dosages were higher than pre-conversion dosages, with a mean conversion ratio of 2.1±0.6 for IR CD-LD and 2.8±0.8 for CLE; >90% of patients took IPX066 3 or 4 times/day, compared with a median of 5 times/day at baseline in both studies. After conversion, daily "off" time significantly decreased, with no significant increase in troublesome dyskinesia. The most common adverse event reported during conversion was nausea, with an incidence of 5.3% for conversion from IR and 7.3% from CLE. CONCLUSIONS: Among PD patients with substantial "off" time, a majority were safely converted to IPX066. The sustained LD profile from the IPX066 formulation allowed an increase in LD dose accompanied by improved motor functions, without increased troublesome dyskinesia.


Subject(s)
Antiparkinson Agents/administration & dosage , Carbidopa/administration & dosage , Levodopa/administration & dosage , Outcome Assessment, Health Care , Parkinson Disease/drug therapy , Aged , Antiparkinson Agents/adverse effects , Antiparkinson Agents/pharmacology , Carbidopa/adverse effects , Carbidopa/pharmacology , Catechols/administration & dosage , Catechols/adverse effects , Catechols/pharmacology , Cross-Over Studies , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Female , Humans , Levodopa/adverse effects , Levodopa/pharmacology , Male , Middle Aged , Nitriles/administration & dosage , Nitriles/adverse effects , Nitriles/pharmacology , Treatment Outcome
3.
Parkinsonism Relat Disord ; 17(4): 285-7, 2011 May.
Article in English | MEDLINE | ID: mdl-21296606

ABSTRACT

Gastroparesis is a very common non-motor feature in Parkinson's disease (PD) patients. However, treatment options are limited and difficult. We present 2 cases of PD patients with excellent response to botulinum toxin type A as treatment for PD-related gastroparesis.


Subject(s)
Botulinum Toxins, Type A/therapeutic use , Gastroparesis/drug therapy , Neuromuscular Agents/therapeutic use , Parkinson Disease/complications , Aged , Female , Gastric Emptying/drug effects , Gastroparesis/etiology , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...